ASX - By Stock
|
PAA |
Re:
Ann: Appointment of Non-Executive Director
|
|
illdrink2that
|
45 |
11K |
9 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
45
|
11K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
illdrink2that
|
209 |
55K |
26 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
209
|
55K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
12 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
895
|
235K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
16 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
895
|
235K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
22 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
895
|
235K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust - Media & News
|
|
illdrink2that
|
57 |
21K |
26 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
57
|
21K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
illdrink2that
|
209 |
55K |
25 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
209
|
55K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
illdrink2that
|
209 |
55K |
39 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
209
|
55K
|
39
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
illdrink2that
|
15 |
4.8K |
33 |
02/06/24 |
02/06/24 |
ASX - By Stock
|
15
|
4.8K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
TOP 100 PAA SHAREHOLDERS 31/5/1924
|
|
illdrink2that
|
5 |
2.3K |
15 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
5
|
2.3K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
illdrink2that
|
19 |
6.2K |
8 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
19
|
6.2K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
illdrink2that
|
19 |
6.2K |
8 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
19
|
6.2K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
illdrink2that
|
19 |
6.2K |
3 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
19
|
6.2K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
7 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
895
|
235K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
illdrink2that
|
85 |
21K |
16 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
21K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
illdrink2that
|
85 |
21K |
25 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
21K
|
25
|
|
ASX - By Stock
|
AFP |
Re:
AFT Pharma reports record earnings, boosted sales and significant launches in US
|
|
illdrink2that
|
2 |
689 |
3 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
2
|
689
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Pharmaust Investor Update
|
|
illdrink2that
|
20 |
5.8K |
29 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
20
|
5.8K
|
29
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
23 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
895
|
235K
|
23
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Pharmaust Investor Update
|
|
illdrink2that
|
20 |
5.8K |
13 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
20
|
5.8K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
18 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
895
|
235K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
illdrink2that
|
58 |
16K |
17 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
58
|
16K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
12 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
895
|
235K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
6 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
895
|
235K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
16 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
895
|
235K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
7 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
895
|
235K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
11 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
895
|
235K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
16 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
895
|
235K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
7 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
895
|
235K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
21 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
895
|
235K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
18 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
895
|
235K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
illdrink2that
|
895 |
235K |
8 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
895
|
235K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
illdrink2that
|
58 |
16K |
26 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
16K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
illdrink2that
|
43 |
12K |
18 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
43
|
12K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
11 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
illdrink2that
|
250 |
65K |
12 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
250
|
65K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
illdrink2that
|
250 |
65K |
19 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
65K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
illdrink2that
|
239 |
65K |
14 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
65K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
illdrink2that
|
239 |
65K |
23 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
239
|
65K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
illdrink2that
|
239 |
65K |
17 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
65K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
illdrink2that
|
239 |
65K |
32 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
65K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
illdrink2that
|
239 |
65K |
28 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
65K
|
28
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
20 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
21 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
10 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
8 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
8 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
14 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
illdrink2that
|
104 |
21K |
7 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
104
|
21K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
illdrink2that
|
1.4K |
371K |
15 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
371K
|
15
|
|